Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,849,308 papers from all fields of science
Search
Sign In
Create Free Account
Vantictumab
Known as:
OMP-18R5
A monoclonal antibody directed against the Wnt signaling pathway with potential antineoplastic activity. Upon administration, vantictumab binds to…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract P3-07-57: Development of a 6-gene qPCR RUO-validated assay as a predictive biomarker for response of vantictumab (OMP-18R5; anti-frizzled) in HER2- breast cancer patients
Chun Zhang
,
G. O'young
,
+13 authors
A. Kapoun
2016
Corpus ID: 77238551
Background: We have developed a monoclonal antibody, vantictumab that blocks canonical WNT/β-catenin signaling through binding of…
Expand
2015
2015
Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer
Chun Zhang
,
F. Cattaruzza
,
+9 authors
A. Kapoun
2015
Corpus ID: 88997061
Background: Vantictumab is a monoclonal antibody that blocks canonical WNT/β-catenin signaling through binding of five FZD…
Expand
2012
2012
Abstract 3356: Development of a novel Wnt pathway antagonist antibody, OMP-18R5, that reduces tumor initiating cell frequency in breast cancer
J. Lewicki
,
F. Axelrod
,
+10 authors
A. Gurney
2012
Corpus ID: 59088903
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The Wnt/beta-catenin pathway, which signals…
Expand